Quarterly report (Form 10-Q)
Johnson & Johnson 10-Q for Quarter ended Sep 27, 2026
Filing excerpt
In the fiscal nine months of 2026, the Company recorded a charge of approximately $0.4 billion primarily related to PreCardia, a non-strategic asset acquired as part of the Abiomed acquisition in 2022.